The Problem of Abnormal Body Weight and Dyslipidemia as Risk Factors for Cardiovascular Diseases in Children and Adolescents with Type 1 Diabetes

Katarzyna Noras,1 Ewa Rusak,2 and Przemysława Jarosz-Chobot2

1Department of Children’s Diabetology, Upper Silesian Child Health Centre, Katowice, Poland
2Department of Children’s Diabetology, Medical University of Silesia, Katowice, Poland

Correspondence should be addressed to Ewa Rusak; rusakewa@gmail.com

Received 21 February 2021; Accepted 13 July 2021; Published 3 August 2021

Diabetes is a disease that affects many people around the world. Its complications are the cause of cardiovascular diseases (CVD) and increased mortality. That is why the search for predictive biomarkers is so important. The aim of the study was to show the prevalence of the problem and risk factors in children and adolescents with type 1 diabetes. These patients are often overweight and obese, and the percentage of lipid disorders is particularly high. The discussed markers of CVD risk in type 1 diabetes include apolipoproteins (apo-B and apo-C3), modified forms of LDL, and the role of high-density lipoprotein (HDL). Recently, a new look at the vasoprotective effect of HDL has appeared, which due to its dysfunctional form in type 1 diabetes may not protect against cardiovascular risk. The HDL proteome in type 1 diabetes has an altered protein composition compared to the healthy population. Another direction of research is determining the importance of trace elements (mainly Mg) in the development of diabetes complications.

1. Introduction

Early prevention of chronic complications of diabetes is of great significance and continues to challenge many professionals. The duration and severity of hyperglycemia are the main factors causing tissue damage and contribute to the development of complications including both microangiopathies (retinal, glomerular, or nerve dysfunction) and macrovascular complications (earlier occurrence of more advanced atherosclerotic changes). Premature atherosclerosis of the arteries, which is the cause of cardiovascular diseases (CVD), is considered to be the main risk factor of almost three times higher mortality in type 1 diabetes [1, 2]. Moreover, advanced complications of diabetes mellitus, such as severe visual impairment, renal replacement therapy, consequences of neuropathy, or sexual dysfunction, restrict patients socially and deteriorate their quality of life. In view of the current increase in the prevalence of type 1 diabetes in children and adolescents, identification of predictive biomarkers and regular screening is very important. The aim of this article is to present the current knowledge about known risk factors for cardiovascular diseases as well as to present the directions of searching for new markers.

2. The Scale of Overweight and Obesity and Dyslipidemia as Risk Factors for Complications in Diabetes

Commonly known risk factors for cardiovascular diseases are excessive body weight and the atherogenic lipid profile correlating with it. The problem of overweight and obesity, which also includes children and adolescents with type 1 diabetes, is related to the globally observed change in eating habits. The prevalence of overweight in these patients, depending on the adopted criterion of overweight and obesity (i.e., BMI ≥ 85 pc or ≥95 pc, BMI ≥ 1SDS or ≥2SDS; as well as being an index of central obesity, waist circumference > 90 cm by gender and age; or WHtR > 0.5 (waist to height ratio) being the
confirmed the established relationship between dyslipidemia (increase in LDL or non-HDL cholesterol) and weight gain, duration of diabetes, or degree of glycemic control (HbA1c). The duration of diabetes mellitus and HbA1c were grouped as follows: <5 years, 5-10 years, and >10 years and HbA1c <7.5%, 7.5-9%, and >9%. The assessment of the influence of the diabetes treatment model on the metabolism spoke in favor of pump therapy compared to intensive insulin therapy with multiple daily injections and was associated with better lipid profile control [11].

The prospective SEARCH study of 1800 young patients with type 1 diabetes showed that the frequency of dyslipidemia (higher non-HDL cholesterol and/or lower HDL cholesterol) was estimated at 29%. Dyslipidemia with longer disease duration, poor glycemic control (HbA1c ≥ 9%), obesity, and elevated blood pressure correlated with recognized cardiovascular risk factors—arterial stiffness index (SI) and augmentation index (Alx). The evaluation of arterial stiffness (measurement of the speed of the arterial wave) and the augmentation index, which is a measure of the size of the reflected wave, characterizing the degree of vessel elasticity, was performed by tonometry using Sphygmocor CPVH. The incidence of increased reflections of the waves/arterial stiffness index was higher in diabetic patients [6].

3. Pathomechanism of Dyslipidemia and Search for New Biomarkers of CVD Risk in Diabetes Mellitus with Particular Emphasis on the Role of Dysfunctional HDL

The atherogenic lipid profile, well documented especially in type 2 diabetes, is characterized by high levels of triglycerides (TG), both fasting and after meal, reduced levels of HDL cholesterol (HDL-C) and normal or slightly elevated levels of LDL cholesterol (LDL-C). In this profile, attention is drawn to the changed composition of lipoproteins composed of a lipid core (rich in TG and cholesterol esters) and a polar shell (containing phospholipids, apolipoproteins, and free cholesterol). It is associated with the presence of dysfunctional HDL and small, dense LDL (sdLDL), the affinity of which for the LDL receptors of liver cells is reduced due to greater susceptibility to oxidation or nonenzymatic glycation. Consequently, their serum presence is prolonged and binding to the arterial wall increases [1, 12]. Accumulation of lipoproteins containing, e.g., apo-B, apo-E, and apo-C3 apolipoproteins, in the arterial wall accelerates the accumulation of macrophages, the formation of foam cells, and the process of atherogenesis [13]. Thus, apolipoprotein-B (apo-B), a carrier protein of low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL), seems to be a marker of cardiovascular disease risk, but its practical usefulness is limited mainly due to the cost of determination [12].

Advanced search for markers of cardiovascular disease risk in type 1 diabetes, extended by the analysis of the composition of modified LDL forms present in the circulating immune complexes (LDL-IC), was carried out among the participants of the prestigious, multicenter DCCT/EDIC study. A
correlation has been demonstrated between the level of ox-LDL (oxidized LDL), MDA-LDL (malondialdehyde-modified LDL), and AGE-LDL (glycosylation-modified LDL) in circulatory immune complexes (ICs) with serious cardiovascular diseases and events and myocardial infarction [14].

Experiments in mouse models with type 1 diabetes show that the relative insulin deficiency (which occurs in suboptimally controlled diabetes) increases the serum levels of apolipoprotein C3 and is associated with accelerated atherosclerosis. As shown in the study, the use of apoC3 antisense oligonucleotides (ASO) removed increased hepatic apoC3 expression which prevented accelerated atherogenesis [13].

There are also reports suggesting that high-density lipoprotein (HDL), commonly regarded as a vasoprotective particle, does not provide protection against cardiovascular risk in type 1 diabetes due to its dysfunctional form [1, 15]. An example is a paper published by Chiesa et al. evaluating the functional properties of HDL by means of endothelial nitric oxide (NO) bioavailability, superoxide (SO) production, and serum paraoxonase activity (PON-1) with the evaluation of endothelial function in a group of teenagers with type 1 diabetes (mean age: 14.6 years, mean HbA1c: 8.3%). In order to assess the severity of inflammation, a risk assessment was made using five proinflammatory markers (EGF: epidermal growth factor; GRO: oncogene regulated by chemokine growth; PDGF-AA and PDGF-BB: platelet growth factors AA and BB; and cCD40L: soluble CD-40 ligand). Increased inflammation index and HDL dysfunction have been demonstrated in patients with early renal dysfunction as assessed by the ACR (albumin/creatinine ratio). In contrast, impaired endothelial function has been reported in patients with high inflammation index and high HDL cholesterol (HDL-C) levels. This fact suggests that a high HDL-C level may be an unfavorable predictor of endothelial function, especially in the presence of chronic inflammation or renal dysfunction [16].

An attempt to assess HDL functionality was also undertaken in a 5-year follow-up of a group of 293 teenagers with type 1 diabetes (mean age: 13.7 years, mean HbA1C: 8.4%) compared to the control group. The HDL function was quantitatively determined by HAE-HDL-apoA-I exchange. Apolipoprotein A-I (apoA-I), which is the main component of the HDL protein, determines its shape and size, takes part in the activation of the lecithin-cholesterol acyl transferase (LCAT) enzyme, and plays an important role in removing cholesterol from peripheral cells by delivering the resulting cholesterol esters to the liver. This protein is considered to be the main component responsible for the antiatherosclerotic effect of HDL. In the above study, the HAE-apoA-I ratio was quantitatively determined, showing that this ratio was lower in diabetic patients and inversely correlated with the HbA1C level. The differences in HDL function appeared soon after the disease onset and persisted over time [17].

The issue of dysfunctional HDL particles was also analyzed in a study by Gourgari et al., in which a broad assessment of HDL protein composition was made in a small group of 26 patients with type 1 diabetes (mean age 16.9 years; mean HbA1c 8.9%; mean HDL 59.7 mg/dl). Comparative assessment of HDL proteomes in adolescents with diabetes compared to a healthy control group was performed. The analysis was carried out using mass spectrometry by quantitative determination of 78 proteins bound with HDL. The altered protein composition of HDL in adolescents with diabetes mellitus compared to the control group was confirmed, despite similar HDL concentration as, for example, significantly increased amounts of complement factor H2 protein (FHR2: factor H-related protein 2), regardless of glycemia. A further analysis of the patients showed that the level of glycemia had an influence on the level of some proteins, i.e., the alpha-1-beta glycoprotein or the alpha-4 trypsln inhibitor [18].

The literature also raises an interesting issue of the relationship between lowered magnesium levels and poor glycemic control and the presence of dyslipidemia in patients with type 1 diabetes. There are reports showing the relationship of hypomagnesemia with an increased risk of atherosclerosis [19] and increased levels of total cholesterol (TC), LDL, and triglyceride fraction cholesterol (TG) and lowered HDL levels [20]. An example of this is the publication by Shahbah evaluating the effect of oral Mg supplementation on glycemic control and lipid profile in children with type 1 diabetes mellitus and coexisting hypomagnesemia (Mg < 1.7 mg/dl). Already after 3 months of oral magnesium oxide supplementation at a dose of 300 mg/day, a significant improvement in glycemic control was observed (HbA1c 10.11% vs. 7.88%) along with a decrease in serum total cholesterol, LDL, and TG concentrations, as opposed to HDL, which increased significantly [21].

4. Summary

Despite pharmacological and technological progress, diabetes still remains one of the most serious and common health problems. Maintaining proper body weight in patients with this condition is very important to reduce the risk of cardiovascular disease. In order to be able to take even more targeted and effective action in the future to prevent the chronic complications of diabetes early, further research is needed to better identify predictive biomarkers. This is especially true for lipid disorders, where both quantitative changes and changes in the function of individual lipoprotein fractions are important. Further research will help to better understand the complex pathomechanism of dyslipidemia and its influence on glycemic control. Perhaps an appropriate model of treatment for diabetes and the associated better glycemic control will contribute to reversing HDL dysfunctional abnormalities which could potentially reduce the risk of vascular complications. Children with type 1 diabetes could particularly benefit as early preventative measures will improve their life expectancy and quality of life.

Conflicts of Interest

The authors declare that there is no conflict of interest.
Acknowledgments

The authors received the financial support for the publication of this article from Medical University of Silesia, Katowice, Poland.

References

[1] J. Schofield, J. Ho, and H. Soran, “Cardiovascular risk in type 1 diabetes mellitus,” *Diabetes Ther*, vol. 10, no. 3, pp. 773–789, 2019.

[2] L. E. Graves and K. C. Donaghe, “Management of diabetes complications in youth,” *Therapeutic Advances in Endocrinology and Metabolism*, vol. 10, pp. 1–12, 2019.

[3] M. Wysocka-Mincewicz, H. Kolołodziejczyk, E. Wierzbicka, and M. Szalecki, “Overweight, obesity and lipids abnormalities in adolescents with type 1 diabetes,” *Pediatric Endocrinology, Diabetes, and Metabolism*, vol. 21, no. 2, pp. 70–81, 2015.

[4] N. Sevaliev, D. Strich, C. Arnon-Ziv, and F. Levy-Khademi, “The metabolic consequences of overweight in a cohort of children with type 1 diabetes,” *Journal of Pediatric Endocrinology & Metabolism*, vol. 32, no. 7, pp. 715–719, 2019.

[5] O. Yayci Köken, C. Kara, G. C. Yılmaz, and H. M. Aydin, “Prevalence of obesity and metabolic syndrome in children with type 1 diabetes: a comparative assessment based on criteria established by the International Diabetes Federation, World Health Organisation and National Cholesterol Education Program,” *Journal of Clinical Research in Pediatric Endocrinology*, vol. 12, no. 1, pp. 55–62, 2020.

[6] E. M. Urbina, S. Isom, R. A. Bell et al., “Burden of cardiovascular risk factors over time and arterial stiffness in youth with type 1 diabetes mellitus: the SEARCH for Diabetes in Youth Study,” *Journal of the American Heart Association*, vol. 8, 2019.

[7] S. Jones, A. R. Khanolkar, and E. Gevers, “Cardiovascular risk factors from diagnosis in children with type 1 diabetes mellitus: a longitudinal cohort study,” *BMJ Open Diabetes Research & Care*, vol. 7, no. 1, p. e000625, 2019.

[8] L. C. S. E. Silva, S. L. B. E. Silva, A. M. S. Oliveira et al., “Hypertriglyceridemic waist and associated factors in children and adolescents with type 1 diabetes mellitus,” *Revista Paulista de Pediatria: Orgão Oficial da Sociedade de Pediatria de Sao Paulo*, vol. 38, 2020.

[9] G. Valerio, E. Mozillo, E. Zito et al., “Alcohol consumption or cigarette smoking and cardiovascular disease risk in youth with type 1 diabetes,” *Acta Diabetologica*, vol. 56, no. 12, pp. 1315–1321, 2019.

[10] G. Kim, J. Divers, N. F. Fino et al., “Trends in prevalence of cardiovascular risk factors from 2002 to 2012 among youth early in the course of type 1 and type 2 diabetes. The SEARCH for Diabetes in Youth Study,” *Pediatric Diabetes*, vol. 20, no. 6, pp. 693–701, 2019.

[11] I. Kosteria, A. Schwandt, E. Davis et al., “Lipid profile is associated with treatment regimen in a large cohort of children and adolescents with type 1 diabetes mellitus: a study from the international SWEET database,” *Diabetic Medicine*, vol. 36, no. 10, pp. 1294–1303, 2019.

[12] A. Sillars and N. Sattar, “Management of lipids abnormalities in patients with diabetes,” *Current Cardiology Reports*, vol. 21, no. 11, p. 147, 2019.

[13] J. E. Kanter, B. Shao, F. Kramer et al., “Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes,” *The Journal of Clinical Investigation*, vol. 129, no. 10, pp. 4165–4179, 2019.

[14] M. F. Lopes-Virella, I. Bebu, K. J. Hunt et al., “Immune complexes and the risk of CVD in type 1 diabetes,” *Diabetes*, vol. 68, no. 9, pp. 1853–1860, 2019.

[15] M. Femlak, A. Gluba-Brzózka, A. Ciałkowska-Rysz, and J. Rysz, “The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk,” *Lipids in Health and Disease*, vol. 16, no. 1, p. 207, 2017.

[16] S. T. Chiesa, M. Charakida, E. McLoughlin et al., “Elevated high-density lipoprotein in adolescents with type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation,” *European Heart Journal*, vol. 40, no. 43, pp. 3559–3566, 2019.

[17] M. Heier, M. S. Borja, C. Brunborg et al., “Reduced HDL function in children and young adults with type 1 diabetes,” *Cardiovascular Diabetology*, vol. 16, no. 1, p. 85, 2017.

[18] E. Gourgari, J. Ma, M. P. Playford et al., “Proteomic alterations of HDL in youth with type 1 diabetes and their associations with glycemic control: a case-control study,” *Cardiovascular Diabetology*, vol. 18, no. 1, p. 43, 2019.

[19] M. E. Atabek, S. Kortoglu, O. Pirgon, and M. Baykara, “Serum magnesium concentrations in type 1 diabetic patients: relation to early atherosclerosis,” *Diabetes Research and Clinical Practice*, vol. 72, no. 1, pp. 42–47, 2006.

[20] A. K. Rodrigues, A. E. Melo, and C. P. Dominguei, “Association between reduced serum levels of magnesium and the presence of poor glycemic control and complications in type 1 diabetes mellitus: a systematic review and meta-analysis,” *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, vol. 14, no. 2, pp. 127–134, 2020.

[21] D. Shahbhab, T. Hassan, S. Morsy et al., “Oral magnesium supplementation improves glycemic control and lipid profile in children with type 1 diabetes and hypomagnesemia,” *Observational Study Medicine*, vol. 96, 2017.